Investigating Abrocitinib Preparation Methods
The patent application WO2020261041A1 details a specific process for preparing abrocitinib [1]. This process aims to provide an improved method for producing the active pharmaceutical ingredient, potentially offering advantages in yield, purity, or efficiency compared to existing methods.
What is Abrocitinib Used For?
Abrocitinib is a medication used to treat moderate-to-severe atopic dermatitis in adults [2]. It functions as a Janus kinase 1 (JAK1) inhibitor, which helps to reduce inflammation and itching associated with the condition [3].
What Other Patents Cover Abrocitinib?
Beyond WO2020261041A1, other patents likely cover different aspects of abrocitinib, including its synthesis, formulations, and therapeutic uses. DrugPatentWatch.com tracks patent landscapes for various pharmaceuticals, which can offer insights into the broader patent protection surrounding a drug like abrocitinib [4].
When Does Abrocitinib's Patent Protection End?
The expiry of patent protection for abrocitinib will determine when generic versions of the drug can be manufactured and sold. Patent expiry dates are crucial for understanding market competition and drug accessibility. Information regarding specific patent expiry timelines for abrocitinib can often be found through specialized patent databases and resources like DrugPatentWatch.com [4].
Who Manufactures Abrocitinib?
Abrocitinib is developed and marketed by Pfizer Inc. [5].